Vestal Point Capital, LP Achilles Therapeutics PLC Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
A detailed history of Vestal Point Capital, LP transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Vestal Point Capital, LP holds 1,500,000 shares of ACHL stock, worth $2.07 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,500,000
Previous 1,500,000
-0.0%
Holding current value
$2.07 Million
Previous $1.53 Billion
11.76%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding ACHL
# of Institutions
21Shares Held
24.2MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$15.3 Million23.86% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.1MShares$5.66 Million2.9% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$3.3 Million0.46% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$2.22 Million0.14% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.99 Million0.27% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $56.3M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...